Establishment Labs (NASDAQ:ESTA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded shares of Establishment Labs (NASDAQ:ESTA - Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Several other analysts have also weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a report on Friday, June 13th. Citigroup upped their target price on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Finally, BTIG Research began coverage on shares of Establishment Labs in a research note on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $51.80.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA traded down $1.39 during midday trading on Friday, hitting $44.15. The company had a trading volume of 166,121 shares, compared to its average volume of 477,366. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $52.41. The company has a debt-to-equity ratio of 5.72, a current ratio of 3.36 and a quick ratio of 2.05. The business's 50-day simple moving average is $38.21 and its 200-day simple moving average is $36.85. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -14.30 and a beta of 0.80.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The business had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the prior year, the firm posted ($0.58) EPS. The company's revenue was up 11.3% compared to the same quarter last year. On average, research analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. purchased a new position in Establishment Labs during the 4th quarter worth approximately $5,494,000. Swiss National Bank increased its stake in shares of Establishment Labs by 2.7% during the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock valued at $1,774,000 after acquiring an additional 1,000 shares during the last quarter. Royce & Associates LP purchased a new position in shares of Establishment Labs during the 4th quarter valued at approximately $4,862,000. William Blair Investment Management LLC increased its position in Establishment Labs by 44.1% in the fourth quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock worth $37,447,000 after buying an additional 248,888 shares during the period. Finally, Sei Investments Co. boosted its stake in Establishment Labs by 22.3% during the fourth quarter. Sei Investments Co. now owns 42,471 shares of the company's stock valued at $1,957,000 after buying an additional 7,731 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.